Protease Inhibitor-Based Regimens for HIV Therapy: Safety and Efficacy

@article{Walmsley2007ProteaseIR,
  title={Protease Inhibitor-Based Regimens for HIV Therapy: Safety and Efficacy},
  author={Sharon L. Walmsley},
  journal={JAIDS Journal of Acquired Immune Deficiency Syndromes},
  year={2007},
  volume={45},
  pages={S5-S13}
}
  • S. Walmsley
  • Published 1 June 2007
  • Medicine
  • JAIDS Journal of Acquired Immune Deficiency Syndromes
Antiretroviral (ARV) treatment strategies for HIV-infected patients continue to evolve. Over the past few years, there was a shift towards the use of nonnucleoside reverse transcriptase inhibitor-based regimens, mostly because of better tolerability, a lower pill burden, and improved adherence relative to using protease inhibitor (PI)-based regimens. Although the 2 strategies do afford similar potency and durability, the PI-based regimens provide a higher genetic barrier to the development of… 
First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better.
TLDR
Darunavir has shown superior antiviral efficacy than lopinavir, particularly in three situations of particular clinical concern: high baseline viral load, low baseline CD4 counts, and suboptimal drug adherence.
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients
TLDR
The CASTLE study is a noninferiority trial in which the efficacy, safety and tolerability of atazanavir-ritonavir and lopinavir–rit onavir were compared in antiretroviral therapy-naive patients.
Regulatory issues in developing new HIV protease inhibitors: risks and benefits
TLDR
The present review highlights the risks and benefits of certain design aspects for studies in treatment-naïve and treatment-experienced patients, including timing of studies, study design options, choice of control arms, and duration of treatment.
Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.
TLDR
Vicriviroc administered with a protease inhibitor plus ritonavir-containing regimen shows potent antiretroviral and immunologic activity sustained over 48 weeks in treatment-experienced patients.
Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis
TLDR
The ATZ/r regimen was generally as effective and well-tolerated as the LPV/ r regimen for the treatment of HIV-1 patients and has no favorable effect on the plasma lipid profile or adipose tissue distribution.
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)
TLDR
Resistance to atazanavir is rare in patients failing the first line of an atazAnavir-based regimen according to the ANRS, andEmergent NRTI resistance-associated mutations were reported in 18% of patients.
The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies
TLDR
The FDA‐approved chemokine (C–C motif) receptor 5 (CCR5) antagonist maraviroc (Selzentry®) is discussed in detail, along with another compound vicriviroc, currently in clinical trials.
Mathematical modelling of host-disease-drug interactions in HIV disease
TLDR
An integrated model of in vivo viral dynamics incorporating drug-specific mutation schemes learned from clinical data is developed and can be modified to incorporate recently elucidated mechanisms of drug action including molecules that target host factors.
...
1
2
3
4
...

References

SHOWING 1-10 OF 81 REFERENCES
Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy: A Systematic Overview
TLDR
NNRTI and boosted PI regimens provide the highest rates of VS in treatment-naive HIV-infected persons and the preservation of future treatment options in antiretroviral therapy (ART)-naive subjects.
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
TLDR
Preliminary data suggest that simplified maintenance therapy with atazanavir-ritonavir alone may be efficacious for maintaining virologic suppression in carefully selected patients with HIV infection.
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
  • R. Hogg, B. Yip, J. Montaner
  • Medicine, Biology
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 1999
TLDR
This population-based cohort study confirms that patients initially treated with a triple-drug antiretroviral regimen comprising 2 NRTIs plus protease inhibitor or a non-NRTI have a lower risk of morbidity and death than patients treated exclusively with 2 N RTIs.
Absence of Resistance Mutations in Antiretroviral-Naive Patients Treated with Ritonavir-Boosted Saquinavir
TLDR
SQV/r plus two NRTIs (1,600/100 mg once daily) is an effective initial treatment option for ARV-naive patients, resulting in a low rate of viral rebound (3.3%) and suggesting that future treatment options are preserved.
3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine
TLDR
Results are presented after 3 years of follow-up in patients who received three-drug therapy with indinavir, zidovudine, and lamivudine in a previously reported study on HIV-infected adults.
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
TLDR
Through 144 weeks, the combination of tenofovir DF, lamivudine, and efavirenz was highly effective and comparable with stavudine for antiretroviral-naive patients and appeared to be associated with better lipid profiles and less lipodystrophy.
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
TLDR
For the initial treatment of HIV-infected adults, a combination regimen that includes lopinavir-ritonavir is well tolerated and has antiviral activity superior to that of a nelfinavIR-containing regimen.
A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients
TLDR
First-line highly active antiretroviral therapy (HAART) with once-daily saquinavir/ritonavir plus two NRTIs showed strong antiviral efficacy over 24 weeks, and should be evaluated in larger prospective randomized clinical trials.
...
1
2
3
4
5
...